PMID- 32112797
OWN - NLM
STAT- MEDLINE
DCOM- 20210401
LR  - 20210401
IS  - 1872-9096 (Electronic)
IS  - 0166-3542 (Linking)
VI  - 177
DP  - 2020 May
TI  - Multivalent DNA vaccine protects against genital herpes by T-cell immune 
      induction in vaginal mucosa.
PG  - 104755
LID - S0166-3542(19)30444-9 [pii]
LID - 10.1016/j.antiviral.2020.104755 [doi]
AB  - Genital herpes is one of the most common sexually transmitted infections (STIs), 
      and it is mainly caused by the neurotropic herpes simplex virus (HSV-2). Not only 
      does this infection cause ulcers, but HSV-2 can also stay in a latent state in 
      the nervous system of the host throughout their lifespan. As a result, many 
      people do not know that they harbor this infection. Moreover, HSV-2 serves as a 
      major risk factor for human immunodeficiency virus (HIV) infection and can be 
      transmitted to the fetus. Despite the high risk of infection and adverse effects, 
      attempts at development of an effective vaccine for HSV-2 have not yet been 
      successful. In this study, we developed a DNA vaccine for HSV-2 (SL-V20). This 
      multivalent DNA vaccine effectively reduced the pathological symptoms of 
      infection and induced efficient elimination of the virus in a mouse model. 
      Intramuscular injection of SL-V20 led to induction of an HSV-2-specific T-cell 
      response in the vagina, the major infection site, and in draining lymph organs. 
      Dendritic cells (DCs), especially basic leucine zipper ATF-like transcription 
      factor 3 (Baft3)(+) DCs and partially interferon regulatory factor 4 (Irf4)(+) 
      DCs, were involved in this T-cell-mediated protective response, while B cells 
      were dispensable for these prophylactic effects. This study demonstrates that 
      SL-V20 offers a novel and effective vaccine against vaginal HSV-2 infection and 
      may be applicable to patients, pending validation in clinical studies.
CI  - Copyright (c) 2020 The Authors. Published by Elsevier B.V. All rights reserved.
FAU - Kim, Hyeon Cheol
AU  - Kim HC
AD  - Graduate School of Medical Science and Engineering, Korea Advanced Institute of 
      Science and Technology (KAIST), Daejeon, 34141, Republic of Korea.
FAU - Oh, Dong Sun
AU  - Oh DS
AD  - Graduate School of Medical Science and Engineering, Korea Advanced Institute of 
      Science and Technology (KAIST), Daejeon, 34141, Republic of Korea.
FAU - Park, Jang Hyun
AU  - Park JH
AD  - Graduate School of Medical Science and Engineering, Korea Advanced Institute of 
      Science and Technology (KAIST), Daejeon, 34141, Republic of Korea.
FAU - Kim, Hyun-Jin
AU  - Kim HJ
AD  - Graduate School of Medical Science and Engineering, Korea Advanced Institute of 
      Science and Technology (KAIST), Daejeon, 34141, Republic of Korea.
FAU - Seo, Yong Bok
AU  - Seo YB
AD  - SL-VAXiGEN Inc., 700 Daewangpanyo-Ro, Bundang-Gu, Seongnam, Gyeonggi, 13488, 
      Republic of Korea.
FAU - Yoo, Hye Jee
AU  - Yoo HJ
AD  - Biomedical Science and Engineering Interdisciplinary Program, KAIST, Daejeon, 
      34141, Republic of Korea.
FAU - Jang, Hye Seon
AU  - Jang HS
AD  - Biomedical Science and Engineering Interdisciplinary Program, KAIST, Daejeon, 
      34141, Republic of Korea.
FAU - Shin, Jua
AU  - Shin J
AD  - SL-VAXiGEN Inc., 700 Daewangpanyo-Ro, Bundang-Gu, Seongnam, Gyeonggi, 13488, 
      Republic of Korea.
FAU - Kim, Chae Won
AU  - Kim CW
AD  - Graduate School of Medical Science and Engineering, Korea Advanced Institute of 
      Science and Technology (KAIST), Daejeon, 34141, Republic of Korea.
FAU - Kwon, Myeong Seung
AU  - Kwon MS
AD  - Department of Obstetrics and Gynecology, College of Medicine, Myunggok Medical 
      Research Center, Konyang University, Daejeon, Republic of Korea.
FAU - Jin, Hyun-Tak
AU  - Jin HT
AD  - ProGen Co., Ltd, 1201, 222, Banpo-daero, Seocho-gu, Seoul, 06591, Republic of 
      Korea.
FAU - Lee, Sung Ki
AU  - Lee SK
AD  - Department of Obstetrics and Gynecology, College of Medicine, Myunggok Medical 
      Research Center, Konyang University, Daejeon, Republic of Korea.
FAU - Oh, Ji Eun
AU  - Oh JE
AD  - Graduate School of Medical Science and Engineering, Korea Advanced Institute of 
      Science and Technology (KAIST), Daejeon, 34141, Republic of Korea. Electronic 
      address: jieun.oh@kaist.ac.kr.
FAU - Lee, Heung Kyu
AU  - Lee HK
AD  - Graduate School of Medical Science and Engineering, Korea Advanced Institute of 
      Science and Technology (KAIST), Daejeon, 34141, Republic of Korea; Biomedical 
      Science and Engineering Interdisciplinary Program, KAIST, Daejeon, 34141, 
      Republic of Korea; KAIST Institute for Health Science and Technology, KAIST, 
      Daejeon, 34141, Republic of Korea. Electronic address: heungkyu.lee@kaist.ac.kr.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200226
PL  - Netherlands
TA  - Antiviral Res
JT  - Antiviral research
JID - 8109699
RN  - 0 (Antibodies, Viral)
RN  - 0 (Vaccines, Combined)
RN  - 0 (Vaccines, DNA)
RN  - 0 (Viral Vaccines)
SB  - IM
MH  - Animals
MH  - Antibodies, Viral/*blood
MH  - Female
MH  - Herpes Genitalis/immunology/*prevention & control
MH  - Herpesvirus 2, Human
MH  - Mice
MH  - Mice, Inbred C57BL
MH  - T-Lymphocytes/*immunology
MH  - Vaccines, Combined/administration & dosage/immunology
MH  - Vaccines, DNA/administration & dosage/immunology
MH  - Vagina/*immunology
MH  - Viral Vaccines/administration & dosage/*immunology
OTO - NOTNLM
OT  - DNA vaccine
OT  - Dendritic cells
OT  - Herpes simplex virus
OT  - Protective immunity
OT  - Sexually transmitted infection
EDAT- 2020/03/01 06:00
MHDA- 2021/04/02 06:00
CRDT- 2020/03/01 06:00
PHST- 2019/08/06 00:00 [received]
PHST- 2020/02/21 00:00 [revised]
PHST- 2020/02/24 00:00 [accepted]
PHST- 2020/03/01 06:00 [pubmed]
PHST- 2021/04/02 06:00 [medline]
PHST- 2020/03/01 06:00 [entrez]
AID - S0166-3542(19)30444-9 [pii]
AID - 10.1016/j.antiviral.2020.104755 [doi]
PST - ppublish
SO  - Antiviral Res. 2020 May;177:104755. doi: 10.1016/j.antiviral.2020.104755. Epub 
      2020 Feb 26.